© Reuters. Palestinians get vaccinated against COVID-19 in Tubas
MELBOURNE (Reuters) – Australia is investigating whether a blood clotting disorder case recorded on Friday is related to the AstraZeneca (NASDAQ 🙂 coronavirus vaccine, said Deputy Chief Medical Officer Professor Michael Kidd. Australian media reported that a 44-year-old man was admitted to a Melbourne hospital with possible clotting days after receiving the vaccine. “Investigators have not confirmed at this time a causal link to the COVID-19 AstraZeneca vaccine, but investigations are ongoing,” Kidd said in a televised briefing. He added that more details are expected to be known on Saturday. The Therapeutic Goods Administration of Australia (TGA), the regulatory agency for drugs and therapies, has previously said that the AstraZeneca vaccine was not associated with an increased overall risk of blood clots.
Disclaimer: Fusion Media
wishes to remind you that the data contained on this website is not necessarily accurate or in real time. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so the prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not appropriate for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business
losses you may incur as a result of the use of this data. Fusion Media or anyone involved with Fusion Media will accept no responsibility for loss or damage as a result of reliance on information, including data, quotes, charts, and buy / sell signals contained on this website. Be fully informed about the risks and costs associated with trading
the financial markets, it
is one of the riskiest forms of investment possible.